UPDATED May 14, 2019, with comment from Medavate. Histogenics (NSDQ:HSGX) said today that it completed another step on its transformation into clinical-stage biopharmaceutical company Ocugen, with a nearly $7 million deal to sell its NeoCart regenerative knee treatment to Medavate. The $6.5 million all-cash deal, signed May 8, will see all of the NeoCart assets pass […]